Note: This document contains side effect information about tbo-filgrastim. Some dosage forms listed on this page may not apply to the brand name Granix.
Applies to tbo-filgrastim: subcutaneous solution.
Cardiovascular
Very common (10% or more): Thrombocytopenia (up to 34%)
Frequency not reported: Aortitis, capillary leak syndrome
In a clinical trial, thrombocytopenia occurred in 34% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.
Gastrointestinal
In a clinical trial, diarrhea occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.[Ref]
Common (1% to 10%): Diarrhea
Frequency not reported: Vomiting[Ref]
Musculoskeletal
Common (1% to 10%): Bone pain, extremity pain
Frequency not reported: Myalgia[Ref]
In a clinical trial, extremity pain occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.[Ref]
Other
In a clinical trial, pyrexia occurred in 8% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.[Ref]
Common (1% to 10%): Pyrexia
Postmarketing reports: Asthenia, fatigue[Ref]
Nervous system
Common (1% to 10%): Headache
In a clinical trial, headache occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.
Immunologic
Common (1% to 10%): Anti-drug antibodies to this drug
Hematologic
Frequency not reported: Fatal splenic rupture, leukocytosis, sickle cell disorders[Ref]
Dermatologic
Frequency not reported: Cutaneous vasculitis
Postmarketing reports: Acute febrile neutrophilic dermatosis, Sweet's syndrome[Ref]
Oncologic
Frequency not reported: Potential for tumor growth stimulatory effects on malignant cells
Hypersensitivity
Frequency not reported: Serious allergic reactions
Respiratory
Frequency not reported: Acute respiratory distress syndrome
Renal
Frequency not reported: Glomerulonephritis
